A new class of drugs is being hailed for its ability to lower LDL, or “bad” cholesterol, and because it can be used by people who cannot tolerate widely used statin drugs. Robert Carhart, MD, an associate professor of medicine and a specialist in cardiology at Upstate, describes how these new injectable drugs, known as PCSK9 inhibitors, help clear artery-clogging LDL. He also discusses their as-yet unknown factors, from high estimated prices to long-tem effects.